Noticias y eventos de Yuanbao Inc (YB)YBYuanbao Inc

Cava Group Upgraded to Buy by UBS with Price Target of $90

Stocks are under pressure this morning as investors confront escalating U.S.-Iran tensions and a highly anticipated inflation report. Futures are pointing lower, with the Nasdaq leading the decline as semiconductor and AI-related stocks continue to retreat from their recent highs.The market's primary focus is the May CPI report, which showed annual inflation accelerating to 4.2% in May, in line with expectations, while core monthly inflation slowed more than anticipated to 0.2%.Geopolitics are adding another layer of uncertainty. Renewed military exchanges between the United States and Iran have increased concerns about energy markets and global economic growth. Oil prices remain volatile as traders assess the risk of disruptions in the Middle East, particularly around the Strait of Hormuz.In pre-market trading, S&P 500 futures fell 0.47%, Nasdaq futures fell 0.72% and Dow futures fell 0.44%.Check out this morning's top movers from around Wall Street, compiled by The Fly.HIGHER -Cava Groupup 2% after UBS upgraded the stock to Buy with a price target of $90, up from $85Hinge Healthup 1% after raising its Q2 and FY26 revenue outlook at its inaugural investor dayUP AFTER EARNINGS -Yuanbaoup 18%Cracker Barrelup 17%Core & Mainup 1%DOWN AFTER EARNINGS -Chewydown 2%J.Jilldown 8%Lakeland Industriesdown 1%LOWER -Dianthusdown 20% after peer Sanofiannounced that its riliprubart Phase 3 study in patients with chronic inflammatory demyelinating polyneuropathy will be stoppedSuper Microdown 12% after announcing a series of concurrent equity and equity-linked financing transactions totaling $7B, in expected aggregate amount as part of its plan to fund the purchase of components to satisfy the AI orders that the company has received in recent weeks for its advanced AI serversNikedown 1% after RBC Capital downgraded shares to Sector Perform with a price target of $50, down from $70

Rui Fang Reports Q4 Revenue of RMB 1.18B in 2025

Reports Q4 revenue RMB 1.18B vs. RMB 888.8M last year. Number of new policiesin the fourth quarter of 2025 was approximately 7.9 million, representing a 34.5% year-over-year increase from approximately 5.9 million in the same period of 2024. Rui Fang, CEO, commented, "We closed the fourth quarter with strong operational and financial momentum, highlighted by a 34.5% year-over-year increase in the number of new policies to approximately 7.9 million. Leveraging AI technology and a network of thousands of models, we delivered personalized product service recommendations, connecting users with coverage needs at lower cost and with higher efficiency, significantly improving the accessibility of insurance. By embedding our proprietary AI and data capabilities across the full consumer service cycle engine, we have delivered measurable gains in system stability, service quality, customer acquisition and cost efficiency. As of year-end, our AI team accounted for over 10% of our total workforce. Our matrix included over 4,900 models capable of analyzing more than 5,700 labels, an increase of more than 290 models and 820 labels compared to 2024, thereby laying a solid foundation for the continuous iteration of our engine. On the product and service front, our strategy remains focused on two key dimensions: accessibility and affordability. We have leveraged AI and our model network to support precise user targeting and personalized services, while developing dedicated products for specific user segments, thereby enhancing insurance accessibility and expanding protection coverage. Meanwhile, we have consistently upgraded coverage benefits, launching products such as our 'Zero-Deductible' Million-RMB Medical Insurance Plan to deliver a strong value proposition and enhanced claims experience. Following the release of the inaugural national 'Commercial Insurance Innovative Drug Catalog' at the end of last year, we partnered with insurers to quickly expand the drug coverage of our Super Medical Insurance Million-RMB Medical Insurance product series, responding to public demand for access to advanced treatments and high-quality medications under the new policy cycle. As a leading player in the insurtech sector, we have achieved solid progress across technological innovation and our product and service offerings in 2025. Through steady business growth, we have further validated the sustainability of our business model while building strong competitive advantages through the deep application of AI technologies. As China enters the 15th Five-Year Plan period, supportive health insurance policies continue to gain traction, while advances in technology are playing an increasingly important role in driving the continued development of inclusive insurance. We will continue to align closely with national policy priorities and strategic priorities, leveraging AI as our core engine to deepen our focus on inclusive insurance. We remain committed to leading the industry forward, contributing to the development of a multi-tier healthcare security system, safeguarding public well-being, and supporting the advancement of the Healthy China initiative."